Acebutolol is a cardioselective beta-adrenergic blocker primarily used in the management of hypertension and certain cardiac arrhythmias. It belongs to the β₁-selective class of beta blockers and is notable for its intrinsic sympathomimetic activity, which can reduce excessive slowing of the heart rate compared with some other beta blockers. Acebutolol was developed as part of the evolution of beta-adrenergic blocking agents aimed at providing effective cardiovascular control with greater selectivity for cardiac β₁ receptors. Following its development and clinical evaluation, it became an established therapeutic option for conditions such as hypertension, ventricular arrhythmias, and other cardiovascular disorders, and has been marketed in various countries under different brand names.
